Clinical manifestations and serum antibodies to carbonic anhydrase IV peptide 4 in patients with definite and probable autoimmune pancreatitis
| Clinical factor | Manifestation | Antibodies to CA IV peptide 4 | p Value | |
|---|---|---|---|---|
| Positive (n = 9) | Negative (n = 20) | |||
| ANA, antinuclear antibody; MPD, main pancreatic duct. | ||||
| *Demonstrated by abdominal ultrasonography and/or computed tomography. | ||||
| †Demonstrated by endoscopic retrograde pancreatography. | ||||
| Age/sex | Age of onset | 64.1 (10.1) | 62.1 (15.4) | NS |
| Male | 6/9 (66.7%) | 12/20 (60.0%) | NS | |
| Immunological tests | γ-globulin (g/dl) | 3.48 (1.34) | 1.73 (0.73) | <0.001 |
| IgG (mg/dl) | 4140 (775) | 2162 (775) | <0.001 | |
| IgM (mg/dl) | 125 (126) | 132 (120) | NS | |
| IgA (mg/dl) | 372 (302) | 210 (86) | <0.05 | |
| ANA (>1+) | 4/9 (44.4%) | 10/19 (52.6%) | NS | |
| Rheumatoid factor | 4/9 (44.4%) | 3/14 (21.4%) | NS | |
| Pancreatic enlargement* | Diffuse | 4/9 (44.4%) | 13/20 (65.0%) | NS |
| Segmental | 4/9 (44.4%) | 4/20 (25.0%) | NS | |
| MPD narrowing† | Diffuse | 6/9 (66.6%) | 7/17 (41.2%) | NS |
| Segmental | 3/9 (33.3%) | 9/17 (52.9%) | NS | |